Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Rhythm Pharmaceuticals, Inc."
Count: 28
Selected: 0
NCT05774756A Trial of Setmelanotide in Acquired Hypothalamic Obesity
NCT05046132Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants
NCT06046443A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
NCT05093634EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
NCT04963231DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
NCT03651765Long Term Extension Trial of Setmelanotide
NCT06239116A Study of RM-718 in Healthy Subjects and in Patients With HO
NCT05194124Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Patients With Specific Gene Defects in the MC4R Pathway
NCT03746522Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
NCT04966741Setmelanotide in Pediatric Patients With Rare Genetic Diseases of Obesity
NCT04725240Open-Label Study of Setmelanotide in Hypothalamic Obesity
NCT02896192Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity
NCT03013543Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
NCT01749137Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants
NCT02041195Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients
NCT02311673Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome
NCT03287960Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity
NCT02849977Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
NCT05183802An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)
NCT03262610Setmelanotide in a Single Patient With Partial Lipodystrophy
NCT04348175A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment
NCT03621007An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Function Mutations in the POMC, PCSK1 or LEPR Genes
NCT03479437The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry
NCT01867437Effects of RM-493 on Energy Expenditure in Obese Individuals
NCT02431442Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers
NCT06420622INDIcators for Clarifying the bAckground of exTreme Obesity in childRen
NCT06239064Early Genetic Identification of Obesity
NCT01849705Melanocortin 4 Receptor Mutations and Obesity-associated Diseases